Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19.

ABSTRACT:

Objective

To compare the efficacy and outcomes with inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with refractory hypoxemia due to COVID-19.

Design

Retrospective Cohort Study.

Setting

Single health system multicenter academic teaching hospitals.

Patients or subjects

Age group of 18-80 years admitted to the medical ICU.

Interventions

Mechanically ventilated patients with COVID-19 infection, who received either iNO or iEPO between March 1st, 2020, and June 30th, 2020.

Measurements and main results

The primary outcome was the change in the PaO2/FiO2 (P/F) ratio 1 hour after initiation of pulmonary vasodilator therapy. Secondary outcomes include P/F ratios on days 1-3 after initiation, positive response in P/F ratio (increase

SUBMITTER: Poonam PBH 

PROVIDER: S-EPMC9236233 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature